Johnson & Johnson (JNJ): Net Income
$26.80B
Year ended 2025-12-28
$16.09B
Trailing 12 months to 2026-09-27
+14.3%
3-year compound annual growth
+12.7%
5-year compound annual growth
+5.7%
10-year compound annual growth
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-28 | $26.80B | +90.6% | 2026-02-11, From 2024-12-30 |
| 2024-12-29 | $14.07B | -60.0% | 2026-02-11, From 2024-01-01 |
| 2023-12-31 | $35.15B | +95.9% | 2026-02-11, From 2023-01-02 |
| 2023-01-01, Fiscal 2022 | $17.94B | -14.1% | 2025-02-13, From 2022-01-03 |
| 2022-01-02, Fiscal 2021 | $20.88B | +41.9% | 2024-02-16, From 2021-01-04 |
| 2021-01-03, Fiscal 2020 | $14.71B | -2.7% | 2023-02-16, From 2019-12-30 |
| 2019-12-29 | $15.12B | -1.2% | 2022-02-17, From 2018-12-31 |
| 2018-12-30 | $15.30B | n/m | 2021-02-22, From 2018-01-01 |
| 2017-12-31 | $1.30B | -92.1% | 2020-02-18, From 2017-01-02 |
| 2017-01-01, Fiscal 2016 | $16.54B | +7.3% | 2019-02-20, From 2016-01-04 |
| 2016-01-03, Fiscal 2015 | $15.41B | -5.6% | 2018-02-21, From 2014-12-29 |
| 2014-12-28 | $16.32B | +18.0% | 2017-02-27, From 2013-12-30 |
| 2013-12-29 | $13.83B | +27.4% | 2016-02-24, From 2012-12-31 |
| 2012-12-30 | $10.85B | +12.2% | 2015-02-24, From 2012-01-02 |
| 2012-01-01, Fiscal 2011 | $9.67B | -27.5% | 2014-02-21, From 2011-01-03 |
| 2011-01-02, Fiscal 2010 | $13.33B | +8.7% | 2013-02-22, From 2010-01-04 |
| 2010-01-03, Fiscal 2009 | $12.27B | -5.3% | 2012-02-23, From 2008-12-29 |
| 2008-12-28 | $12.95B | +22.4% | 2011-02-25, From 2007-12-31 |
| 2007-12-30 | $10.58B | n/a | 2010-03-01, From 2007-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Johnson & Johnson (JNJ) | 2025-12-28 | $26.80B | +90.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $20.64B | +94.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $18.25B | +6.6% |
| Pfizer Inc (PFE) | 2025-12-31 | $7.77B | -3.2% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $4.23B | -1.2% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $7.05B | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $6.52B | -51.3% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $1.41B | n/m |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $4.50B | +2.1% |
Compare JNJ, LLY, MRK, PFE side by side · Screen every company in Pharmaceutical Preparations ↗